Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients With Genetically Confirmed Barth Syndrome
Latest Information Update: 21 Apr 2026
At a glance
- Drugs Elamipretide (Primary)
- Indications Barth syndrome
- Focus Therapeutic Use
- Acronyms 4TAZPower
- Sponsors Stealth BioTherapeutics
Most Recent Events
- 21 Apr 2026 New trial record